Hypoxia‐induced increase in sphingomyelin synthase 2 aggravates ischemic skeletal muscle inflammation
The FEBS Journal · 2025
DOI: 10.1111/febs.17379 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, 2025. Verfasst von Hinano Mizugaki und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Veterinary Medicine, Azabu University, Sagamihara, Japan. Hauptthemen laut MEDLINE: Transferases (Other Substituted Phosphate Groups), Ischemia, Muscle, Skeletal, Inflammation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, NIH HHS, NIBIB NIH HHS.
Abstract (Originalsprache)
Critical limb ischemia (CLI) is the most advanced stage of peripheral arterial disease, posing a high risk of mortality. Sphingomyelin, a sphingolipid synthesized by sphingomyelin synthases (SMSs) 1 and 2, plays an essential role in signal transduction as a component of lipid rafts. However, the role of sphingomyelin in the inflammation of ischemic skeletal muscles remains unclear. In this study, we analyzed the roles of sphingomyelin and SMSs in CLI‐induced myopathy using a mouse hindlimb ischemia model. We observed that hypoxia after CLI triggered an increase in SMS2 levels, thereby elevating sphingomyelin concentrations in ischemic skeletal muscles. The expression of SMS2 and sphingomyelin was induced by hypoxia in C2C12 myotubes and regulated by the prolyl hydroxylase domain enzyme. Additionally, SMS2 deficiency suppressed skeletal muscle inflammation after CLI, attenuated the phosphorylation of inhibitor of κBα (IκBα), and reduced the nuclear translocation of nuclear factor κB (NFκB) p65. Meanwhile, the administration of sphingomyelin hampered skeletal muscle inflammation by inhibiting IκBα phosphorylation and NFκB p65 nuclear translocation and extending inflammation post‐CLI. Our results suggest that hypoxia‐induced enhancement in SMS2 levels and the consequent increase in sphingomyelin expression levels promote inflammation in ischemic muscle tissues via the NFκB pathway and propose sphingomyelin as a potential therapeutic target in patients with CLI and other hypoxia‐related inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Veterinary Medicine, Azabu University, Sagamihara, Japan.
- Center for Human and Animal Symbiosis Science, Azabu University, Sagamihara, Japan.
- Graduate School of Engineering Science, Osaka University, Japan.
- Department of Radiology, Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.
- Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan.
- One Health Research Center, Hokkaido University, Sapporo, Japan.
ORCID-Profile: Masaki Nagane, Tadashi Yamashita
Förderung
- Japan Society for the Promotion of Science
- NIH HHS
- NIBIB NIH HHS
- Azabu University
- National Institutes of Health
Zitieren
APA
Mizugaki, H., Nagane, M., Sato-Akaba, H., Kmiec, M., Kuppusamy, P., Yasui, H., Inanami, O., Murakami, H., Aihara, N., Kamiie, J., Mizunoya, W., Yasuda, I., Fukuyama, T., Naya, Y., & Yamashita, T. (2025). Hypoxia‐induced increase in sphingomyelin synthase 2 aggravates ischemic skeletal muscle inflammation. The FEBS Journal. https://doi.org/10.1111/febs.17379
Vancouver
Mizugaki H, Nagane M, Sato-Akaba H, Kmiec M, Kuppusamy P, Yasui H, et al. Hypoxia‐induced increase in sphingomyelin synthase 2 aggravates ischemic skeletal muscle inflammation. The FEBS Journal. 2025. doi:10.1111/febs.17379
BibTeX
@article{Mizugaki2025,
author = {Mizugaki, Hinano and Nagane, Masaki and Sato-Akaba, Hideo and Kmiec, Maciej and Kuppusamy, Periannan and Yasui, Hironobu and Inanami, Osamu and Murakami, Hironobu and Aihara, Naoyuki and Kamiie, Junichi and Mizunoya, Wataru and Yasuda, Ibuki and Fukuyama, Tomoki and Naya, Yuko and Yamashita, Tadashi},
title = {Hypoxia‐induced increase in sphingomyelin synthase 2 aggravates ischemic skeletal muscle inflammation},
journal = {The FEBS Journal},
year = {2025},
doi = {10.1111/febs.17379}
}
EUVIMED